Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!
Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times ... Read More
Lupin receives FDA approval for seizures medication Diazepam Rectal Gel
Lupin announced that its subsidiary Novel Laboratories has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application for ... Read More
Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health
Lupin Limited said that MedQuímica Indústria Farmacêutica, its 100% subsidiary in Brazil, has agreed to acquire all rights to nine drugs from Bausch Health Companies’ ... Read More
Glenmark gets marketing approval for Ryaltris in 13 European countries
Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13 countries across the European Union (EU) and ... Read More